Premium
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention
Author(s) -
Garcia David,
Ageno Walter,
Bussey Henry,
Eikelboom John,
Margaglione Maurizio,
Marongiu Francesco,
Moia Marco,
Palareti Gualtiero,
Pengo Vittorio,
Poli Daniela,
Schulman Sam,
Witt Dan,
Wittkowksy Ann,
Crowther Mark
Publication year - 2009
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21470
Subject(s) - medicine , vitamin k , vitamin k antagonist , intensive care medicine , warfarin , atrial fibrillation
Oral anticoagulant therapy with coumarins is widely\udused for the prevention and treatment of venous and\udarterial thrombosis. The most common complication of\udvitamin K antagonist therapy is bleeding, with major\udbleeding events occurring in 1–3% of patients annually.\udAlthough a number of potential predictors for bleeding\udhave been described, little research is available to provide\udevidence-based guidelines for the prevention of\udbleeding. To address this knowledge gap, we assembled\uda panel of international experts and posed a series of\udfocused clinical questions. The experts were asked to\udperform a systematic literature review and summarize the\udresults of that review within the context of their clinical\udquestion. In many cases, data were lacking and the\udexperts were asked to supplement their answer with clinical\udexpertise. To minimize bias the reviews were vetted\udby three internationally recognized scholarly bodies. Our\udgoal in this project is to provide ‘‘best evidence’’ for\udclinicians faced with the problem of minimizing the risk\udof bleeding in patients on vitamin K antagonist therap